I kind of like the idea.
Basically, we are paying twice as much as other countries, mostly b/c they are able to negotiate as a huge bloc, and U.S. insurers negotiate as smaller entities (Medicare uses the *average* domestic price, which is essentially a gigantic hidden subside to drug companies.
What the article doesn't touch on is how it will affect non-Medicare U.S. patients - there is a good chance they will have to foot some portion of this change. (Thanks, Trump).
Worth noting, FTFA:
"What they’re saying: The Obama administration proposed a similar policy in 2016, and industry groups killed it. There’s pretty decent chance that could happen here, too."